View Older Stories
-
Active equity option families in first 30-minutes of trading according to Track Data are: BAC C AAPL AMGN
-
Notable Analyst Rating Changes 11/04: KIM, PHM, QCOM, HMA Upgraded; MPWR, PT, SWIR, K Downgraded
-
Notable Analyst Rating Changes 10/25: C, CCL, PFG, PPDI Upgraded; MSFT, BKD, WFT, ATHN Downgraded
-
Notable Analyst Rating Changes 09/29: CPE, ENDP, SCS, SPIL Upgraded; AZN, JCG, AMGN, WBSN Downgraded
-
Citi maintains a 'Buy' on Amgen Inc (AMGN); Management Bullish On Prolia Long-Term
-
Notable Analyst Rating Changes 08/16: DYN, CHK, GNW, VMW Upgraded; COCO, DEG, CPLA, ESI Downgraded
-
Citi Comments on Disease-Modifying Antirheumatic Drug Market - 'Not Immune to a Tough Economy'
-
Citi Upgrades Amgen (AMGN) to Buy
-
Amgen (AMGN) Lower Despite Q3 Beat As Company Looks To Address Prolia Issues with FDA (Update)
-
Active equity option families in first 30 minutes of trading according to Track Data are: AAPL C BAC AMGN
-
David Moenning's Daily State of the Markets: Subtle, Yet Effective
-
Notable Analyst Rating Changes 9/2: TXT, CBE, SI, PAY, BBD Upgraded; ROK, GIS, HOLX, DHI, RYL, NVAX Downgraded
-
Notable Analyst Rating Changes 8/14: C, RF, PVH, GPS Upgraded; AMGN, AVB, IRE, TCO Downgraded
-
Citi Downgrades Amgen (AMGN) to Hold
-
Notable Analyst Rating Changes 8/11: FLR, SATS, DEO, QLGC, BEXP Upgraded; YUM, MBI, S Downgraded
-
Active equity option families in first 30 minutes of trading according to Track Data are: C AMGN GE MSFT
-
Sanofi-Aventis (SNY) On the Prowl For A Mega-Deal In the U.S.?
-
Top 10 News Items 6/1-6/5: GM IS BANKRUPT; Jobs Report Comes in Much Better-Than-Expected; Equity Offerings Still All The Rage
-
Barclays Gets Bullish On US Biotechnology Sector (BBH)
-
Notable Analyst Rating Changes 5/6: DIS, IGT, AEO, AZO Upgraded; BCS, FITB, VCLK, CBL Downgraded
-
Highlights From Amgen's (AMGN) Q1 Conference Call: Guides Lower for FY09 Revenues
-
Notable Analyst Rating Changes 4/24: RIMM, AMGN, INFA, CAKE Upgraded; MAR, SPWRA, TOL, PTR Downgraded
-
David Moenning's Daily State of the Markets: 4/24
-
David Moenning's Daily State of the Markets: 4/13
-
Citigroup (C) and GM (GM) Out of The Global Dow, Is Dow 30 Next?
-
Citi Reiterates a 'Buy' Rating on Teva Pharmaceutical (TEVA)
-
David Moenning's Daily State of the Markets: 3/6
-
David Moenning's Daily State of the Markets: 1/27
-
David Moenning's Daily State of the Markets: 1/23
-
Citi Maintains 'Buy' Rating on Amgen (AMGN), Adds Stock to Top Picks Live List
-
David Moenning's Daily State of the Markets: 10/23
-
David Moenning's Daily State of the Markets: 7/30
-
Notable Analyst Rating Changes 7/29: AMGN, AFL, DPS Upgraded; VNDA, ZRAN, SNDK Downgraded
-
David Moenning’s Daily State of the Markets: 07/29
-
Citi Upgrades Amgen (AMGN) to Buy
-
Equity option family volume leaders in first 30-minutes of Trading: BAC JPM AMGN C
-
David Moenning's Daily State of the Markets: 4/25
-
David Moenning's Daily State of the Markets: 3/18
-
Citi Maintains 'Hold' Rating on Amgen (AMGN), Comments on FDA Briefing Documents
-
Citi Analyst Comments on Court Decision Between Amgen (AMGN) and Roche
-
David Moenning's Daily State of the Markets: 1/25
